Curis Inc
NASDAQ:CRIS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Curis Inc
NASDAQ:CRIS
|
US |
|
Transcoal Pacific Tbk PT
IDX:TCPI
|
ID |
|
Amfil Technologies Inc
OTC:FUNN
|
CA |
|
S
|
Shin Yang Shipping Corporation Bhd
KLSE:SYSCORP
|
MY |
Curis Inc
Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. The company is headquartered in Lexington, Massachusetts and currently employs 60 full-time employees. The company went IPO on 2000-08-01. The firm is focused on the development of therapeutics for the treatment of cancer. Its clinical stage drug candidates are Emavusertib and CI-8993. Emavusertib is an orally available small molecule inhibitor of Interleukin-1 receptor-associated kinase 4 (IRAK4) which is undergoing testing in a Phase I open-label dose escalating clinical trial in patients with non-Hodgkin lymphomas. CI-8993 is a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation (VISTA). Its pipeline also includes Fimepinostat, CA-170 and CA-327. Fimepinostat is a small molecule that inhibits the activity of histone deacetylase (HDAC), and phosphotidyl-inositol 3 kinase (PI3) enzymes. CA-170 is a small molecule antagonist of VISTA and PDL1. CA-327 is a small molecule antagonist of PDL1 and TIM3, which is a pre-IND stage oncology drug candidate.
Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. The company is headquartered in Lexington, Massachusetts and currently employs 60 full-time employees. The company went IPO on 2000-08-01. The firm is focused on the development of therapeutics for the treatment of cancer. Its clinical stage drug candidates are Emavusertib and CI-8993. Emavusertib is an orally available small molecule inhibitor of Interleukin-1 receptor-associated kinase 4 (IRAK4) which is undergoing testing in a Phase I open-label dose escalating clinical trial in patients with non-Hodgkin lymphomas. CI-8993 is a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation (VISTA). Its pipeline also includes Fimepinostat, CA-170 and CA-327. Fimepinostat is a small molecule that inhibits the activity of histone deacetylase (HDAC), and phosphotidyl-inositol 3 kinase (PI3) enzymes. CA-170 is a small molecule antagonist of VISTA and PDL1. CA-327 is a small molecule antagonist of PDL1 and TIM3, which is a pre-IND stage oncology drug candidate.
Trial focus: Curis is prioritizing NHL programs — a registrational TakeAim study in primary CNS lymphoma (PCNSL) and a new proof-of-concept study in CLL — ahead of AML.
PCNSL enrollment: Enrollment is on track; management reiterated a rough 12–18 month timeframe to full enrollment and suggested possible filing timing in 2027 after required follow-up.
CLL plans: A proof-of-concept study adding emavusertib to BTKi in patients with partial responses is activated in the U.S. and Europe; initial data are expected at ASH in December 2026.
AML signal: In an AML triplet study (emavusertib + azacitidine + venetoclax), 5 of 8 evaluable patients achieved MRD conversion in early cohorts, supporting further interest but AML is lower near-term priority.
Financials: Reported Q4 2025 net income of $19.4 million ($1.23/sh) driven by a $27.2 million one-time noncash gain from the Erivedge sale; company expects no meaningful revenue in 2026.
Operating runway: Cash as of Dec 31, 2025 plus $20.2 million received in Jan 2026 and up to an additional $20.2 million tied to a warrant exercise (linked to dosing the 5th CLL patient) should fund operations into H2 2027.
Capital allocation: Management will prioritize spend on PCNSL (registrational) and CLL (proof-of-concept) and defer larger AML investments until additional resources are available.
